Quote this publication Share Print

AXELER

-
Opinions on drugs - Posted on Jan 06 2011

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance (boxes of 30 and 90) and approved for use by hospitals (boxes of 30, 50 and 90).

-


Clinical Benefit

Substantial

The actual benefit of AXELER products is substantial.


Clinical Added Value

no clinical added value

AXELER 20 mg/5 mg, 40 mg/5 mg and 40 mg/10 mg fixed-dose combinations of olmesartan medoxomil 20 or 40 mg and amlodipine besilate 5 or 10 mg provide no improvement in actual benefit (IAB V) in comparison with concurrent use of the two active substances taken separately.


Contact Us

Évaluation des médicaments

See also

All our publications